Literature DB >> 34431510

New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.

P Bortoluzzi1, S Ferrucci2, D Galimberti3, F Garavelli4, F Pozzo Giuffrida4, A Pizzati1, A V Marzano2,5, C Mapelli3.   

Abstract

Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.
© 2021 British Association of Dermatologists.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34431510     DOI： 10.1111/bjd.20706

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  2 in total

1.  Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

Authors:  Mélanie Hébert; Susan Ruyu Qi; Eunice You; Mathieu Mercier; Patricia-Ann Laughrea
Journal:  BMJ Open Ophthalmol       Date:  2022-05

2.  Ocular surface disease is common in moderate-to-severe atopic dermatitis patients.

Authors:  Roselie E Achten; Daphne S Bakker; Chantal M van Luijk; Marlot van der Wal; Marlies de Graaf; Femke van Wijk; Nicolaas P A Zuithoff; Lisa P van der Rijst; Celeste M Boesjes; Judith L Thijs; Joke H de Boer; Marjolein S de Bruin-Weller
Journal:  Clin Exp Allergy       Date:  2022-03-18       Impact factor: 5.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.